134
Participants
Start Date
July 7, 2022
Primary Completion Date
June 28, 2030
Study Completion Date
August 14, 2030
Ribociclib
Participants continue ribociclib as was administered in their parent study
Letrozole
Participants continue ribociclib in combination with letrozole as was administered in their parent study
Anastrozole
Participants continue ribociclib in combination with anastrozole as was administered in their parent study
Goserelin
Participants continue ribociclib in combination with goserelin as was administered in their parent study
Tamoxifen
Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
Fulvestrant
All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
Novartis Investigative Site, San Borja
Novartis Investigative Site, Johannesburg
Novartis Investigative Site, Cape Town
Novartis Investigative Site, Taipei
Eastchester Center for Cancer Care, The Bronx
Novartis Investigative Site, Taipei
Novartis Investigative Site, Trujillo
Novartis Investigative Site, Diyarbakır
Summit Cancer Care, Savannah
John D Archbold Memorial Hospital, Thomasville
Mid Florida Hematology And Onc Ctr, Orange
Novartis Investigative Site, Izmir
University Hospitals of Cleveland Seidman Cancer Center, Cleveland
Novartis Investigative Site, Malatya
Indian Univ Health Goshen Center forCancer, Goshen
Novartis Investigative Site, Meldola
Duly Health and Care, Plainfield
Novartis Investigative Site, San Pedro G G
Highlands Oncology Group, Fayetteville
Oklahoma Cancer Specialists and Research Institute, Tulsa
Millennium Research Clin Develop, Houston
Poudre Valley Hospital, Fort Collins
Ironwood Cancer and Research Centers, Chandler
Beverly Hills Cancer Center, Beverly Hills
Novartis Investigative Site, San José
Novartis Investigative Site, Hanoi
Novartis Investigative Site, Beijing
Novartis Investigative Site, Delhi
Novartis Investigative Site, Singapore
Novartis Investigative Site, Changchun
Novartis Investigative Site, Harbin
Novartis Investigative Site, Beirut
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Qingdao
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Changsha
Novartis Investigative Site, Kunming
Novartis Investigative Site, Bhubaneshwar
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Pokfulam
Novartis Investigative Site, Chouf
Northern Light Mercy Hospital, Portland
Englewood Health, Englewood
The Valley Hospital-Luckow Pavillion, Paramus
Novartis Investigative Site, San Juan
Novartis Investigative Site, Natal
Novartis Investigative Site, Ijuí
Novartis Investigative Site, Florianópolis
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Sao Jose Rio Preto
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Shijiazhuang
Novartis Investigative Site, Heraklion Crete.
Novartis Investigative Site, Osaka
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Koto Ku
Novartis Investigative Site, Beirut
Novartis Investigative Site, Gdansk
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Loures
Novartis Investigative Site, Porto
Novartis Investigative Site, Pretoria
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Sant Joan Despí
Novartis Investigative Site, Kecioren Ankara
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY